Hematologic Oncology Update cover image

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting

Hematologic Oncology Update

00:00

Is Rucksolitinib a Marker of Longevity?

Rucksolitinib improves the symptoms as well i wanted to ask you about pi3 kinase inhibition and breast cancer. A lot of the agents that are used particularly in breast cancer seem to have a lot of side effects including lymphomas. How is this drug tolerated in this setting? I don't know whether other people find it confusing but you hear aboutPi3 kinase inhibitors and breast canceryou hear about lymphomas, how is this drug tolerated in this setting  i wanted to Ask You About Pi3 Kinase Inhibiting Breast Cancer was published on November 14th by The New England Journal of Medicine (NEJ) at 10:30am ET. To order your

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app